AstraZeneca’s AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19

 AstraZeneca’s AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19

AstraZeneca’s AZD7442 Meet its Primary Endpoints in P-III TACKLE Trial for the Treatment of COVID-19

Shots:

  • The P-III TACKLE trial evaluates the safety & efficacy of AZD7442 (600mg, IM) as monothx. vs PBO in a ratio (1:1) in 903 outpatients aged ≥18yrs. who were non-hospitalized with COVID-19 & symptomatic for ≤7 days
  • The trial met its 1EPs i.e., 50% reduction in risk of severe COVID-19 or death from any cause, was well tolerated. In prespecified analysis, 67% reduction in risk of severe COVID-19 or death from any cause
  • Additionally, 90% of patients were at high risk of progression to sev COVID-19 including co-morbidities. The company will discuss data with the authorities. On Oct 5, 2021, the company had submitted a request to the US FDA for EUA of AZD7442 to treat prophylaxis of COVID-19

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: Al Jazeera

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post